Santen Pharmaceutical Co., Ltd. financial statements, including revenue, expenses, profit, and loss

The total revenue of SNPHY for the last quarter is 532.96 M USD, and it's 2.33% higher compared to the previous quarter. The net income of Q4 23 is 202.05 k USD.